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Objectives This study assessed whether the results of major, potentially practice-altering cardiovascular trials were influ-
enced by the authors’ self-declared financial conflicts of interest (FCOI). Secondary objectives included assess-
ment of trial outcomes by source of funding, by FCOI subtype, and by trial endpoints.
Background Financial conflicts of interest, ubiquitous in cardiovascular medicine because of significant investigator-industry
collaborations, potentially can influence trial outcomes.
Methods A MEDLINE search was performed using the MeSH term cardiovascular disease limited to randomized controlled
trials and clinical trials published from January 1, 2000, through April 15, 2008, in 3 high-impact journals. Two
reviewers independently abstracted data from the published article. Chi-square tests, Fisher exact tests, and
multivariate logistic regression were used to assess the associations between FCOI and study characteristics and
between FCOI and trial outcomes.
Results Of the 550 articles reviewed, 51.1% satisfied FCOI criteria, including at least one of the following: stock owner-
ship, employee, speaker’s bureau, and consultant). Of the 538 articles providing sponsorship information, 34.6%
reported funding solely by nonprofit organizations, 48.3% reported funding solely by industry, and 17.1% re-
ported funding by a combination. Prevalence of FCOI significantly increased with level of industry funding: 21.5%
(none), 50.0% (shared), 75.0% (industry solely, n  281, p  0.0001). However, no differences in reporting of
favorable results were detected when articles were analyzed by self-declared FCOI (60.5% vs. 59.5% in those
with and without, odds ratio: 1.04, p  0.81). This result was upheld in multivariate analysis.
Conclusions Authors’ self-declared FCOI and source of funding do not seem to impact outcomes in major cardiovascular clini-
cal trials. (J Am Coll Cardiol 2013;61:1137–43) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.10.056The Institute of Medicine in its 2009 position statement
defined conflicts of interest as “circumstances that create a
risk that professional judgments or actions regarding a
primary interest will be unduly influenced by a secondary
interest” (1). Collaboration between academic medicine and
From the *Heart and Vascular Center, MetroHealth Campus of Case Western
Reserve University, Cleveland, Ohio; †Division of Cardiology, Beth Israel Deaconess
Medical Center, Harvard Medical School, Boston, Massachusetts; ‡Department of
Medicine, James J. Peters VA Medical Center, Bronx, New York; §Zena and Michael
A. Weiner Cardiovascular Institute, Mount Sinai School of Medicine, New York,
New York; Centre for Research on Inner City Health, the Keenan Research Centre
in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, and Dalla Lana
School of Public Health, University of Toronto, Toronto, Ontario, Canada; ¶Applied
Health Research Centre, Li Ka Shing Knowledge Institute, University of Toronto,
Toronto, Ontario, Canada; and the #Peter Munk Cardiac Centre University of
Toronto, Toronto, Ontario, Canada. The authors have reported that they have no
relationships relevant to the contents of this paper to disclose.Manuscript received July 9, 2012; revised manuscript received October 1, 2012,
accepted October 8, 2012.industry has produced revolutionary treatments that have
contributed significantly to improvements in public health.
The influence of this academia–industry collaboration on
the integrity of research is debated actively and is subjected
to appropriate scrutiny in the public domain because of
perceptions that the outcomes of some high-impact clinical
trials may be influenced by financial conflicts of interest
See page 1144
(FCOI). Financial conflicts of interest are very important
because of their potential for undue influence on the
judgments of institutions and individuals, along with
potentially threatening the integrity of scientific investi-
gation, objectivity of medical education, and quality of
patient care, all of which can lead to erosion of vital
public trust (1).
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Conflicts of Interest Do Not Impact Trial Results March 19, 2013:1137–43Indeed, a recent systematic re-
view revealed patients’ belief that
financial transactions affect phy-
sician behavior and need to be
disclosed. The study also sug-
gested that patients, physicians,
and research participants believed that financial transactions
weaken the quality of research and evidence (2). Similarly, a
review of researcher attitudes illustrated the concern that
investigators have about the impact of financial ties on the
choice of research topic, research conduct, and publication (3).
urther, studies have suggested that trials funded by for-
rofit organizations are more likely to be associated with
avorable outcomes compared with those that are funded by
ot-for-profit organizations (4–8). These concerns from
atients, physicians, researchers, and organizations have led
o both external regulation and self-regulation by academic
edical centers and the pharmaceutical industry to demon-
trate greater transparency and accountability. Regulation
easures include the mandatory registration of all clinical
rials on ClinicalTrials.gov, requirements for accurate and
ystematic reporting of authors’ conflicts of interest by major
ournals, declaration of potential FCOI by staff and faculty
hysicians at university and hospital websites with a recent
irective to declare exact dollar amounts received from
ndustry, and development of guidelines by the pharmaceu-
ical industry strictly regulating potential contributions by
ndustry to academic centers and individual physicians
9–12). In their recent comprehensive document, the Insti-
ute of Medicine detailed the various FCOI types and
uggested clear policy measures—both individual and insti-
utional—to address these issues (1,13).
Broadly stated, FCOI in medicine can be present in
esearch, education, medical practice, and guideline devel-
pment. Additionally, management of cardiovascular dis-
ase represents a substantial component of the U.S. health-
are budget, with significant contributions from expensive
ovel therapeutic agents including drugs, devices, and strat-
gies. The management of cardiovascular disease and stroke
ccounts for 16% of the overall healthcare expense in the
nited States. The 2008 estimate of direct and indirect
osts of cardiovascular care in the United States was $297.7
illion (14). In a national survey, cardiologists were twice as
ikely as family practitioners to receive payments from
ndustry, explained by the fact that cardiologists are viewed by
ndustry as opinion leaders and as being more likely to be
nvolved in research efforts (15). Therefore, potential conflicts
f interest in cardiovascular research and publication represent
critically important field that needs investigation.
Recognizing the ability of major randomized cardiovas-
ular disease trials published in high-impact journals to
hange practice patterns, the primary aim of this study was
o examine the impact of authors’ self-declared FCOI on
he outcomes of major cardiovascular trials. Secondary aims
Abbreviation
and Acronym
FCOI  financial conflicts
of interestncluded assessment of trial outcomes by source of funding, bonflict of interest subtype (detailed in the following text),
nd trial endpoints (clinical vs. surrogate).
To perform an even more in-depth analysis of FCOI in
ajor cardiovascular trials, we performed tertiary analyses
xamining associations between self-reported FCOI and:
) type of intervention (drug, device, or other); 2) study
esign (superiority or noninferiority); 3) choice of primary
nd secondary endpoints (clinical vs. surrogate); 4) statistical
nalysis (independent vs. nonindependent); and 5) presence
r absence of registration on ClinicalTrials.gov. Addition-
lly, trial outcomes, favorable versus unfavorable, were
nalyzed by independence of statistical analysis.
ethods
rticle selection. A MEDLINE search was conducted via
ubMed to identify articles for inclusion. We limited our
valuation to major cardiovascular trials published in 3
igh-impact general medical journals, namely The New
ngland Journal of Medicine, the Lancet, or the Journal of the
American Medical Association. The initial search consisted of
articles with the MeSH term cardiovascular disease and was
imited to randomized controlled trials and clinical trials
ublished from January 1, 2000, through April 15, 2008.
Two independent reviewers (R.E. and K.S.) evaluated the
elected publications. They examined in detail the study title,
bstract, and methods to ensure that each study represented a
andomized trial. Observational studies, cohort studies, com-
entaries, letters, meta-analyses, and review articles were
xcluded (Fig. 1). The remaining eligible articles were ab-
tracted systematically via a standardized data collection form
s part of the Clinical Trials Reporting Database.
The FCOI were divided into 2 broad categories: FCOI
resent and FCOI absent. Any author was deemed to have
n FCOI if they met the following criteria: stock ownership,
mployee, consultant, or presence on a speakers’ bureau. An
COI was deemed not present if the author only received
esearch funding or reported no conflict (16). Prior studies
ave demonstrated that research funding alone did not have
n impact on trial results (17). In addition, the National
nstitutes of Health’s recent revision of FCOI standards and
irectives that describes significant FCOI by the following
riteria: salary, consulting honoraria, equity interest, own-
rship interest, spouses and children’s FCOI, intellectual
roperty rights, and travel grants—which does not include
esearch funding (18). Studies not stating any financial
isclosures were excluded.
Trial outcomes were deemed positive or favorable if the
ew intervention (drug, device, combination, or other) was
ound to be effective with respect to the primary endpoint
ith statistical significance. Trials were deemed to have
linical endpoints if the primary endpoint was clinical in
ature with mortality or morbidity parameters. The end-
oint was considered surrogate if it was a radiological or
aboratory measure and did not include mortality or mor-
idity parameters. Trials were considered to be statistically
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March 19, 2013:1137–43 Conflicts of Interest Do Not Impact Trial Resultsindependent if a biostatistician with an academic faculty
appointment or who was employed by a government re-
search institute performed the analysis.
Statistical analysis. The associations between FCOI, trial
characteristics, and outcomes were evaluated by comparing
proportions using the chi-square or Fisher exact tests or
logistic regression when more than 2 categories were present
and a reference group was defined. We also estimated univar-
iate odds ratios with 95% confidence intervals to quantify the
degree of association. A multivariate logistic regression was
used to examine further the association between FCOI and a
favorable trial result, adjusting for the study characteristics.
SAS software version 9.2 (SAS Institute, Cary, North Caro-
lina) was used for all statistical analyses, and 2-sided p values
0.05 were considered statistically significant.
Results
Primary analysis: authors’ self-declared FCOI and trial
outcomes. Of the 769 PubMed citations identified by the
From the Pubmed Search 769 arcles
were identiied that met the criteria: 
- MESH Term: Cardiovascular Disease
- Journals: 
o NEJM or
o JAMA or
o Lancet 
- Time Period: January 01, 2000 to April 15, 
2008 
- Publication Type:  
o Randomized Clinical Trial or
o Clinical Trial 
43 Observational Studies 
52 Cohort Studies 
47 Review Articles 
77 Commentaries/Letters 
E
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u
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e
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Analyzed articles: 550
Figure 1 Flowchart Showing Literature
Search Identifying Studies of Interest
Of the 769 studies identified by the search, 550 were included in this analysis.
JAMA  Journal of the American Medical Association; NEJM  New England
Journal of Medicine.initial search, 605 met initial search criteria (Fig. 1). Ofthese, 550 articles were selected after screening for articles
meeting the prespecified inclusion criteria. In 269 (48.9%)
articles, FCOI were absent (39 with no conflict, 230
research funding only), and in 281 (51.1%) articles, FCOI
were present (including at least 1 of the following: stock
ownership, employee, speaker’s bureau, or consultant). Ar-
ticles were predominantly multicenter trials (89.1%) and
reported safety data (71.2%) (Table 1). Financial conflicts of
interest were more prevalent in multicenter than in single-
center studies (55.5% vs. 15.0%, p  0.0001) and in articles
reporting safety data (59.5% vs. 31.0%, p  0.0001). More
studies published in The New England Journal of Medicine
had an FCOI reported than in the Lancet (60.1% vs. 39.4%,
p  0.0001), but not in the Journal of the American Medical
ssociation (60.1% vs. 51.1%, p  0.07). Studies conducted
n the United States or Canada alone (33.5%) were less
ikely to report FCOI than international studies (34.2%) or
hose conducted both in the United States and Canada
32.4%, p  0.003 and p  0.0005, respectively). When
xamining the overall impact of FCOI on the likelihood of
aving a significantly beneficial trial result (Table 2), no
ifferences were noted (60.5% vs. 59.5% in those with and
ithout financial conflict, unadjusted odds ratio: 1.04, 95%
onfidence interval: 0.74 to 1.47, p  0.81). The effect of
COI on reporting of favorable outcomes remained not
ignificant even after adjusting for type of study, center
ocation, trial registration, funding source, and intervention
ype (odds ratio: 1.13, 95% confidence interval: 0.74 to 1.71,
 0.58).
econdary analysis: financial conflicts of interest and trial
esults by source of funding, conflict of interest subtype,
nd trial endpoints. Overall, 34.6% (n 186) were funded
olely by not-for-profit organizations, 48.3% (n 260) were
unded by industry, and 17.1% (n  92) were funded by a
combination. Of the trials sponsored by industry, 75.0%
reported FCOI compared with 50.0% for those with com-
bination funding and 21.5% for trials funded by not-for-profit
organizations alone (p 0.0001 and p 0.0001, respectively).
When separated by type of financial disclosure, favorable
versus unfavorable trial results also were distributed simi-
larly: no conflict: 38.2% vs. 39.6%, stock ownership: 15.5%
vs. 13.2%, sponsor employee: 14.6% vs. 12.3%, speakers’
bureau: 15.8% vs. 16.8%, and consultancy: 5.8% vs. 8.2%,
research funding: 6.4% vs. 8.2%, and no mention of finan-
cial conflict: 3.9% vs. 1.8% (p  0.57).
When separated by type of financial disclosure, the
distribution of favorable trials results was similar (p 0.57):
59.2% (n  213), 63.8% (n  80), 64.0% (n  75), 58.4%
(n  89), 51.4% (n  37), 53.9% (n  39), and 76.5%
(n  17) for no conflict, stock ownership, sponsor em-
ployee, speakers’ bureau, consultancy, research funding, and
no mention of financial conflict, respectively.
Trials with a surrogate endpoint versus a clinical endpoint
were not more likely to have a favorable result (68.7% [n 
99] vs. 58.1% [n  451], p  0.051), but were less likely to
report a FCOI (38.4% vs. 53.9%, p  0.005). Intervention
l Associ
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Conflicts of Interest Do Not Impact Trial Results March 19, 2013:1137–43types were noted to be 58.9% drug (n  324), 9.8% device
(n  54), 2.9% drug versus device (n  16), and 28.3%
other (n  156, i.e., behavioral, dietary, procedural, or
Journal and Trial Characteristics in Articles Repand Not Reporting Authors’ F nancial Conflict oTable 1 Journal nd Trial Characteristics inand Not Reporting Authors’ Financi
All
(n  550)
Journal
NEJM 208 (37.8)
Lancet 160 (29.1)
JAMA 182 (33.1)
Type of trial
Single center 60 (10.9)
Multicenter 490 (89.1)
Center location
United States only or Canada only 184 (33.5)
International 188 (34.2)
United States and Canada 178 (32.4)
Registered on ClinicalTrials.gov
Yes 120 (21.9)
No 427 (78.1)
Funding source
Industry only 260 (48.3)
Nonindustry only 186 (34.6)
Industry and nonindustry 92 (17.1)
Intervention type
Drug 324 (58.9)
Device 54 (9.8)
Drug or device 16 (2.9)
Other 156 (28.4)
Comparator
Placebo 209 (64.5)
Active 115 (35.5)
Safety data reported
Yes 390 (71.2)
No 158 (28.8)
Values are n (%).
COI  conflict of interest; JAMA  Journal of the American Medica
Association Between Authors’ Financial ConflicPrimary Outcome, Hypothesi Type, and IndepenTable 2 Association Between Authors’ FinaPrimary Outcome, Hypothesis Type,
All COI Pre
Primary analysis
Primary outcome
Significant and beneficial 330 170 (6
Nonsignificant 220 111 (3
Secondary analyses
Hypothesis type
Noninferiority/equivalence 132 81 (3
Superiority 344 163 (6
Primary endpoint type
Clinical 451 243 (8
Surrogate 99 38 (1
Independent statistical analysis
Yes 271 136 (5
No 233 129 (4Values are n (%).
CI  confidence interval; OR  odds ratio. Other abbreviation as in Table 1nondevice surgical) forms of intervention. Among drug only
trials (n  324), 64.5% were placebo controlled. Device
studies reported a significantly higher proportion of finan-
grestl Reporting
nflict of Interest
COI Present
(n  281)
COI Absent
(n  269) p Value
125 (60.1) 83 (39.9) Reference
63 (39.4) 97 (60.6) 0.001
93 (51.1) 89 (48.9) 0.07
9 (15.0) 51 (85.0) 0.001
272 (55.5) 218 (44.5)
93 (50.5) 91 (49.5) Reference
66 (35.1) 122 (64.9) 0.003
122 (68.5) 56 (31.5) 0.001
82 (68.3) 38 (31.7) 0.001
198 (46.4) 229 (53.6)
195 (75.0) 65 (25.0) Reference
40 (21.5) 146 (78.5) 0.001
46 (50.0) 46 (50.0) 0.001
197 (60.8) 127 (39.2) 0.575
35 (64.8) 19 (35.2) Reference
7 (43.8) 9 (56.3) 0.136
42 (26.9) 114 (73.1) 0.001
126 (60.3) 83 (39.7) 0.72
67 (58.3) 48 (41.7)
232 (59.5) 158 (40.5) 0.001
49 (31.0) 109 (69.0)
ation; NEJM  New England Journal of Medicine.
terest andStatistical AnalysisConflict of Intere t and
Independent Statistical Analysis
COI Absent OR (95% CI) p Value
160 (59.5) 1.04 (0.74–1.47) 0.81
109 (40.5)
51 (22.0) 1.76 (1.17–2.66) 0.006
181 (78.0)
208 (77.3) 1.88 (1.20–2.93) 0.005
61 (22.7)
135 (56.5) 0.81 (0.57–1.15) 0.25
104 (43.5)ortinf InteArtic
al Cot of Indentcial
and
sent
0.5)
9.5)
3.2)
6.8)
6.5)
3.5)
1.3)
8.7).
d
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March 19, 2013:1137–43 Conflicts of Interest Do Not Impact Trial Resultscial disclosure than other intervention studies (64.8% [n 
54] vs. 26.9% [n  156], p  0.0001), but similar rates to
rug studies (60.8% [n  324], p  0.57) or drug or device
tudies (43.8% [n  16], p  0.14). Among drug-only
tudies, no difference in financial disclosures was observed
etween placebo-controlled and active controlled trials
60.3% [n  209] vs. 58.3% [n  115], p  0.72).
ertiary analysis: associations between FCOI and inde-
endent statistical analysis, hypothesis type, and registration
n ClinicalTrials.gov. Independent statistical analyses were
eported in 271 (53.8%) of 504 trials. They did not seem to
ave a significant association with FCOI (51.3% vs. 56.5%,
 0.25), with 56.7% of statistically independent studies
and 69% of nonstatistically independent studies reporting
favorable outcomes (p  0.008). Trials registered on Clini-
calTrials.gov were more likely to report significant FCOI
(68.3%, n  120) versus those not registered at the website
(46.4%, n  427, p  0.0001). When classified by hypoth-
esis type, 72.3% (n  344) of trials had a superiority
hypothesis and 27.7% (n 132) of trials had an equivalence
and noninferiority hypothesis. Equivalence and noninferi-
ority hypothesis trials were more likely than superiority trials
to report FCOI (61.4% vs. 47.4%, p  0.006).
Discussion
Our data demonstrate that authors’ self-declared FCOI are
ubiquitous in major cardiovascular clinical trials and do not
seem to have an impact on their outcomes. A subanalysis
conducted on the basis of the type of FCOI also does not
seem to influence trial outcomes. Furthermore, the selec-
tion of surrogate over clinical endpoints does not seem to
increase the likelihood of favorable trial results in major
cardiovascular clinical trials published in high-impact
journals.
On September 27, 2007, the Congress enacted a U.S. law
that expanded the types of clinical trials that must be
registered on ClinicalTrials.gov (18). Before this date,
registration essentially was a voluntary process. As part of
the same effort, the International Committee of Medical
Journal Editors has required all authors of original research
who plan to publish articles in member journals to register
their clinical trials into the clinical trials database (19). This
mechanism subjects investigators to generalized professional
accountability and academic oversight by minimizing the
potential for selective reporting, omitting of primary out-
comes, and inclusion of post hoc secondary outcomes
(20,21). Fines and penalties also are proposed for trials not
published within 1 year of closeout. As part of uniform
FCOI disclosure, the International Committee of Medical
Journal Editors also has developed a standard FCOI decla-
ration form, which has been implemented by high-impact
journals (22).
The results of our study are surprising when evaluated in
the light of previously published literature, but perhaps
represent the most comprehensive and multidimensionalanalysis of FCOI in major cardiovascular clinical trials to
date. Prior studies examining the impact of study funding
sources on outcomes have noted that those funded by
for-profit entities have a higher likelihood of reporting
favorable results (8,23,24). However, in contrast to prior
studies that analyzed trials on the basis of the source of
funding of the overall trial, our study evaluated the potential
impact of authors’ self-declared FCOI on study outcomes
from several vantage points.
In our study, trials registered on ClinicalTrials.gov were
more likely to have significant reported FCOI. This result is
not unexpected because authors registering their studies
voluntarily are more likely to have been forthcoming of their
potential financial conflicts. The enactment of the registra-
tion mandate is likely to improve transparency in clinical
trials reporting and to further ameliorate publication bias.
The higher likelihood of a significant FCOI in trials
originating in the United States and Canada—whether
solely North American or international—also is expected
because most large pharmaceutical and device corporations
are headquartered in this region, increasing the likelihood of
collaborative research and potential conflicts. Also, not
surprisingly, multicenter trials were more likely to include
authors with an FCOI largely because of the large
number of collaborators, larger study size, and greater
expenditure, usually borne by industry. Similarly, trials
funded by not-for-profit entities were less likely to report
significant FCOI than trials conducted in collaboration
or those sponsored by for-profit organizations. Regard-
less of these variables, trial outcomes did not seem to have
been swayed in one direction.
As previously noted, noninferiority and equivalence de-
sign trials were in the minority compared with trials with a
superiority hypothesis. These findings lend further support
our primary outcomes because noninferiority and equiva-
lence design trials generally require a smaller sample size
than superiority trials and are more likely to be adopted as
the preferred hypothesis, especially by for-profit entities.
We observed a greater proportion of nonstatistically inde-
pendent studies reporting favorable findings relative to
statistically independent studies. Although this finding is
interesting and suggests that statistical independence may
influence study findings, further research is needed for
verification.
The differences between our analysis and prior reports are
multifactorial. Apart from the ClinicalTrials.gov mandate,
an increasing number of major academic institutions in the
United States and Canada have made significant strides
toward more transparency and improved regulation, advanc-
ing their conflict-of-interest policies. There is some evi-
dence that major academic institutions are implementing
steps to limit and reconcile potential FCOI to minimize
their impact on trial results, but nationwide data on this
important subject are sparse (12,25). Notwithstanding the
belief that FCOI declaration is trending in the right
direction, a significant proportion of drug and device trials
c1142 Aneja et al. JACC Vol. 61, No. 11, 2013
Conflicts of Interest Do Not Impact Trial Results March 19, 2013:1137–43still are conducted in nonacademic settings, often by stand-
alone research organizations with the aid of clinical research
organizations, with approval from multi-institutional insti-
tutional review boards that potentially can bypass the rigor
of an academic institutional review board. This trend is
thought to have resulted from the expense and difficulties
encountered with conducting clinical research in academic
institutes with layers of bureaucracy.
Given the financial imperative for pharmaceutical and
device companies to be profitable, it is essential to
strengthen systems such as trial registration and reporting of
financial disclosures to increase transparency in medical
research. Because the cost of developing a single successful
drug is nearly $1.5 billion and the logistics of patient
recruitment and follow-up are increasingly challenging,
government funding cannot be expected to be a substitute
for industry-sponsored trials (26). Thus, it is no surprise
that up to 62% of clinical drug trials now are funded by the
pharmaceutical industry (27). Although this industry-
academia collaboration has produced unprecedented thera-
peutic and diagnostic tools, efforts to understand the impact
of potential biases and addressing them are essential. Al-
though our findings support the notion that FCOI do not
affect the reporting of positive outcomes in pivotal cardio-
vascular trials, further investigation into whether these
findings hold true in specific trial designs, including drug
trials, device trials, and placebo-controlled trials, is of
interest.
Despite the rigorous data extraction, the results of our
study are determined on the basis of self-declared FCOI.
Although reassuring, this may represent the tip of the
iceberg, because a recent study suggests significant under-
reporting of FCOI by guideline authors (28). We under-
stand that the study’s reliance on self-report of FCOI is a
limitation. Although imperfect, this method is used widely
and is most practical. However, this approach could lead to
misclassification, the extent of which is uncertain. We
acknowledge that because many FCOI situations may not
have been reported, this study has limited applicability to
policy making, but further research may provide interesting
information at a granular level. In addition, the complete
absence of an FCOI in several industry-sponsored trials is
surprising, but potentially can be explained by research
funding alone not being included as a significant FCOI.
The potential impact of publication bias also is difficult to
assess and overcome and could have impacted the results of
our study. We believe that studies with null findings would
have been the most likely to have gone unregistered or
unpublished, which would bias our findings toward the null
hypothesis, limiting the impact on our conclusions. The true
impact of mandatory trial registration on ClinicalTrials.gov
on publication bias will become available in the ensuing
years. The current trends suggest that compared with 2004
through 2007, the number of trials registered on Clinical-
Trials.gov between 2007 and 2010 has increased signifi-
antly, with fewer missing data elements. However, mosttrials being registered on ClinicalTrials.gov are small, with
fewer than 100 patients (29). Additionally, we limited our
study to the top 3 general medical journals for practical
reasons. The potential impact of casting an even wider net
and including articles from other cardiovascular journals is
unknown. We believe that this field currently is in a state of
active evolution, and further steps are needed to ensure
complete declaration of authors’ FCOI. In addition, FCOI
declaration alone probably does not eliminate potential or
perceived problems stemming from FCOI, but represents
an important first step in eradicating their impact (30).
Recently, there has been recognition of the potential impact
of lecturers’ and physicians’ FCOI on medical students’
education and future practice (31).
Conclusions
Our findings suggest no significant influence of reported
FCOI on the likelihood of a trial having favorable results.
However, current strategies for reporting of FCOI are in a
state of evolution and require uniform implementation. An
effective but ongoing surveillance and standardization of
procedures at the individual and institutional level, as
suggested by the Institute of Medicine, is required to
address this phenomenon.
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